EUVIMEDEUVIMED entdecken
Crossref

Dapagliflozin attenuates cardiomyocyte hypertrophy by inhibiting KEAP1–NRF2-mediated ferroptosis pathway

Liying Liang, Qiujuan Wang, Honghui Zhen, Xi Chen, Qin He, Mingli Wang, Ye Hong, Siyu Zeng, Xiaoyan Li, Yanfang Chen iD

Journal of Pharmacy and Pharmacology · 2026

DOI: 10.1093/jpp/rgag120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Liying Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510440, P.R. China. Hauptthemen laut MEDLINE: Kelch-Like ECH-Associated Protein 1, Ferroptosis, NF-E2-Related Factor 2, Myocytes, Cardiac. Die Arbeit nennt 73 Literaturangaben. Gefördert von: Guangzhou Municipal Science and Technology Bureau, Research Project of Guangdong Yiyang Healthcare Charity Foundation, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Myocardial hypertrophy is a common pathological process in various cardiovascular diseases and may ultimately lead to heart failure. As a sodium-glucose cotransporter 2 inhibitor, dapagliflozin (DAPA) has been demonstrated to be cardioprotective, in addition to its hypoglycemic effect. However, the precise mechanism of DAPA in myocardial hypertrophy remains unclear.

Methods

H9C2 rat cardiomyoblast cell line were subjected to isoproterenol (ISO)-induced hypertrophy and erastin-induced ferroptosis, and treated with DAPA, ferrostatin-1, KEAP1 activator K67, or inhibitor ML334. Hypertrophic markers and cell surface area were assessed by quantitative real-time polymerase chain reaction and rhodamine-phalloidin staining. Ferroptosis was evaluated by measuring glutathione (GSH), malondialdehyde, reactive oxygen species, lipid peroxidation, intracellular ferrous iron, and mitochondrial membrane potential. Protein expression of KEAP1, NRF2, solute carrier family 7 member 11, and GSH peroxidase 4 was determined by western blot. Key findings DAPA attenuated ISO-induced cardiomyocyte hypertrophy and suppressed ferroptosis by inhibiting KEAP1 to activate NRF2, upregulating downstream targets. GSH peroxidase 4 knockdown abolished DAPA’s protective effects. KEAP1 reactivation with K67 reversed DAPA-mediated cardioprotection, whereas KEAP1 inhibition with ML334 recapitulated it.

Conclusions

DAPA exerts a protective role in myocardial hypertrophy by inhibiting KEAP1–NRF2-mediated ferroptosis pathway, providing novel insights into the potential mechanism and application of DAPA on cardiovascular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kelch-Like ECH-Associated Protein 1FerroptosisNF-E2-Related Factor 2Myocytes, CardiacGlucosidesCardiomegalyBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsAnimalsRatsCell LineSignal TransductionIsoproterenolReactive Oxygen SpeciesLipid PeroxidationCardiotonic Agents

Stichwörter der Autor:innen

DAPAKEAP1–NRF2 signaling pathwaycardiomyocyte hypertrophyferroptosislipid peroxidation

Substanzen

Kelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2KEAP1 protein, ratNfe2l2 protein, ratGlucosidesIsoproterenolReactive Oxygen SpeciesCardiotonic AgentsBenzhydryl CompoundsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510440, P.R. China.
  • Department of Pharmacy, The Sixth Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, Guangdong 510655, P.R. China.
  • Department of Pharmacy, The Eighth Affiliated Hospital of Southern Medical University, Foshan, Guangdong 528308, P.R. China.
  • School of Pharmacy, Guangzhou Health Science College, Guangzhou, Guangdong 510450, P.R. China.

ORCID-Profile: Yanfang Chen

Förderung

  • Guangzhou Municipal Science and Technology Bureau
  • Research Project of Guangdong Yiyang Healthcare Charity Foundation
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Science and Technology Project of Guangzhou

Zitieren

APA

Liang, L., Wang, Q., Zhen, H., Chen, X., He, Q., Wang, M., Hong, Y., Zeng, S., Li, X., & Chen, Y. (2026). Dapagliflozin attenuates cardiomyocyte hypertrophy by inhibiting KEAP1–NRF2-mediated ferroptosis pathway. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgag120

Vancouver

Liang L, Wang Q, Zhen H, Chen X, He Q, Wang M, et al. Dapagliflozin attenuates cardiomyocyte hypertrophy by inhibiting KEAP1–NRF2-mediated ferroptosis pathway. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgag120

BibTeX
@article{Liang2026,
  author = {Liang, Liying and Wang, Qiujuan and Zhen, Honghui and Chen, Xi and He, Qin and Wang, Mingli and Hong, Ye and Zeng, Siyu and Li, Xiaoyan and Chen, Yanfang},
  title = {Dapagliflozin attenuates cardiomyocyte hypertrophy by inhibiting KEAP1–NRF2-mediated ferroptosis pathway},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2026},
  doi = {10.1093/jpp/rgag120}
}
Kostenlos starten →